These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 3073960)
1. The epipodophyllotoxin derivatives VM26 and VP16: experimental and clinical aspects. Dombernowsky P; Hansen HH Eur J Haematol Suppl; 1988; 48():49-57. PubMed ID: 3073960 [No Abstract] [Full Text] [Related]
2. In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay. Matsushima Y; Kanzawa F; Miyazawa N; Sasaki Y; Saijo N Anticancer Res; 1986; 6(5):921-4. PubMed ID: 3026235 [TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships among glycosidic derivatives of 4'-demethylepipodophyllotoxin and epipodophyllotoxin, showing VM26- and VP16-213-like activities. Gupta RS; Chenchaiah PC; Gupta R Anticancer Drug Des; 1987 Aug; 2(1):1-12. PubMed ID: 3449081 [TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide. A pharmacodynamic rationale? Allen LM; Tejada F; Okonmah AD; Nordqvist S Cancer Chemother Pharmacol; 1982; 7(2-3):151-6. PubMed ID: 7083456 [TBL] [Abstract][Full Text] [Related]
5. The podophyllotoxin derivatives VP16-213 and VM26. Issell BF Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593 [TBL] [Abstract][Full Text] [Related]
6. Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors. Issell BF; Tihon C; Curry ME Cancer Chemother Pharmacol; 1982; 7(2-3):113-5. PubMed ID: 7083450 [TBL] [Abstract][Full Text] [Related]
7. The epipodophyllotoxin derivatives VM-26 and VP-16-213, 1976-1979, a review. Nissen NI; Dombernowsky P; Hansen HH; Pedersen AG Recent Results Cancer Res; 1980; 74():98-106. PubMed ID: 7003663 [TBL] [Abstract][Full Text] [Related]
8. Etoposide and teniposide in the treatment of acute leukemia. Björkholm M Med Oncol Tumor Pharmacother; 1990; 7(1):3-10. PubMed ID: 2187120 [TBL] [Abstract][Full Text] [Related]
9. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213. Rivera G; Avery T; Roberts DW Eur J Cancer (1965); 1975 Sep; 11(9):639-47. PubMed ID: 1220978 [No Abstract] [Full Text] [Related]
10. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide. Long BH; Musial ST; Brattain MG Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377 [TBL] [Abstract][Full Text] [Related]
11. Etoposide (VP16) and teniposide (VM26): novel anticancer drugs, strongly mutagenic in mammalian but not prokaryotic test systems. Gupta RS; Bromke A; Bryant DW; Gupta R; Singh B; McCalla DR Mutagenesis; 1987 May; 2(3):179-86. PubMed ID: 3325741 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Teniposide (VM26) and etoposide (VP16-213) in children with cancer. Evans WE; Sinkule JA; Crom WR; Dow L; Look AT; Rivera G Cancer Chemother Pharmacol; 1982; 7(2-3):147-50. PubMed ID: 7083455 [TBL] [Abstract][Full Text] [Related]
13. [New antineoplastic drugs of the podophyllotoxin derivative group]. Robak T; Płuzańska A Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283 [No Abstract] [Full Text] [Related]
14. Antimetastasis effect of two derivatives of epiposophyllotoxin in mice. Cattan A; Pourny C; Carpentier Y; Cattan E; Barouh M Eur J Cancer (1965); 1976 Oct; 12(10):797-805. PubMed ID: 976288 [No Abstract] [Full Text] [Related]
15. New anticancer drug class. Fuerst ML JAMA; 1983 Mar; 249(12):1539, 1543. PubMed ID: 6827733 [No Abstract] [Full Text] [Related]
16. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. Long BH; Musial ST; Brattain MG Cancer Res; 1985 Jul; 45(7):3106-12. PubMed ID: 3839166 [TBL] [Abstract][Full Text] [Related]
17. The clinical pharmacology of VM26 and VP16-213. A brief overview. Creaven PJ Cancer Chemother Pharmacol; 1982; 7(2-3):133-40. PubMed ID: 7044592 [No Abstract] [Full Text] [Related]
18. Skin ulceration potential without therapeutic anticancer activity for epipodophyllotoxin commercial diluents. Dorr RT; Alberts DS Invest New Drugs; 1983; 1(2):151-9. PubMed ID: 6678864 [TBL] [Abstract][Full Text] [Related]